TGFB2 and neoplasm: In the case of grade IV astrocytoma, a highly malignant brain tumor, a whole‐cell vaccine approach involves genetically altering autologous tumor cells to hinder the secretion of TGF‐beta2, with the intention of impeding mechanisms by which tumors evade the immune system and fostering clinically effective anti‐tumor immune responses.53